Diffuse Large B Cell Lymphoma Clinical Trials in Richmond, Virginia

4 studies are recruiting for diffuse large b cell lymphoma in Richmond, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Virginia Cancer Institute ( Site 0148), Richmond, Virginia
    Locations
    275 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06717347 on ClinicalTrials.gov

  2. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

    Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
    Locations
    115 in total
    Run by
    BeOne Medicines

    See if you can join NCT05006716 on ClinicalTrials.gov

  3. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    VCU Massey Comprehensive Cancer Center, Richmond, Virginia
    Locations
    87 in total
    Run by
    SWOG Cancer Research Network

    See if you can join NCT05633615 on ClinicalTrials.gov

  4. Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

    This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Virginia Commonwealth University, Richmond, Virginia
    Run by
    Virginia Commonwealth University

    See if you can join NCT06846463 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.